Brokers Set Expectations for Aptose Biosciences Inc.’s FY2025 Earnings (TSE:APS)
Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Stock analysts at Oppenheimer raised their FY2025 earnings per share estimates for Aptose Biosciences in a report issued on Tuesday, August 2nd. Oppenheimer analyst M. Biegler now expects that the biotechnology company will post earnings of $0.42 per share for the year, up from their prior estimate of $0.38. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($0.85) per share.
Aptose Biosciences (TSE:APS – Get Rating) (NASDAQ:APTO) last posted its earnings results on Monday, May 9th. The biotechnology company reported C($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.18) by C$0.03.
Separately, Jonestrading restated a “buy” rating and issued a C$5.00 price target on shares of Aptose Biosciences in a report on Friday, June 3rd.
Aptose Biosciences Stock Performance
Shares of Aptose Biosciences stock opened at C$1.08 on Thursday. The firm has a market cap of C$99.61 million and a price-to-earnings ratio of -1.23. The stock’s 50-day moving average is C$1.09 and its 200-day moving average is C$1.36. Aptose Biosciences has a one year low of C$0.90 and a one year high of C$3.91. The company has a debt-to-equity ratio of 0.81, a current ratio of 9.83 and a quick ratio of 9.51.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptose Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.